gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 11 Dec 2014.

V-raf murine sarcoma viral oncogene homolog B1

BRAF
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: KRAS, Raf, CAN, HAD, EGFR
Papers using BRAF antibodies
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF
Supplier
Pal Soumitro, In PLoS ONE, 2009
... All primary antibodies were purchased from Cell Signaling Technology except the following: anti-BRAF from Santa Cruz Biotechnology, anti-CRAF from BD Biosciences, ...
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults
Supplier
LiVolsi Virginia A et al., In CytoJournal, 2000
... The amplified products were electrophoresed on a 1.2% gel at 110 V for 1.5 hours and the BRAF bands (~220 bp) were cut using sterile blade and purified using Qiagen Gel Extraction Kit (Hilden, ...
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
Supplier
Brinker Achim et al., In Current Chemical Genomics, 1993
... Unconjugated B-Raf antibody was from Santa Cruz Biotechnology (sc-5284), pMEK1/2 antibody from ...
Papers on BRAF
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.
New
Impact
Zhang et al., Cambridge, United States. In Nature, 10 Jan 2015
We also synthesized a library consisting of 70,290 guides targeting all human RefSeq coding isoforms to screen for genes that, upon activation, confer resistance to a BRAF inhibitor.
microRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis.
New
Mann et al., Sydney, Australia. In Pigment Cell Melanoma Res, 09 Jan 2015
We examined global miRNA expression profiles in fresh-frozen metastatic melanomas in relation to clinical outcome and BRAF mutation, with validation in independent cohorts of tumors and sera.
Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada.
New
Thabane et al., Brookline, United States. In Pharmacoeconomics, 09 Jan 2015
OBJECTIVE: To evaluate the cost effectiveness of dabrafenib versus dacarbazine and vemurafenib as first-line treatments in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma from a Canadian healthcare system perspective.
Familial cardiofaciocutaneous syndrome in a father and a son with a novel MEK2 mutation.
New
Zenker et al., Ankara, Turkey. In Am J Med Genet A, 08 Jan 2015
CFC syndrome is caused by dominant mutations in one of the four genes BRAF, MEK1, MEK2, and KRAS.
Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA.
New
Shima et al., Japan. In Oncogene, 08 Jan 2015
UNLABELLED: Somatic mutations in the gene encoding the catalytic subunit of protein phosphatase 6 (Ppp6c) have been identified in malignant melanoma and are thought to function as a driver in B-raf- or N-ras-driven tumorigenesis.
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.
New
Impact
Lane et al., Boston, United States. In Nat Med, 08 Jan 2015
In several human tumors, mutations in the gene encoding GNB1 co-occurred with oncogenic kinase alterations, including the BCR-ABL fusion protein, the V617F substitution in JAK2 and the V600K substitution in BRAF.
Targeting RAS-ERK signalling in cancer: promises and challenges.
New
Impact
Poulikakos et al., Princeton, United States. In Nat Rev Drug Discov, 01 Jan 2015
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes.
Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease.
New
Impact
Amoura et al., Metz, France. In J Clin Oncol, 24 Dec 2014
BRAF(V600E) mutations have been observed in half of patients with Langerhans cell histiocytosis (LCH) and in 50% to 100% of patients with Erdheim-Chester disease (ECD) patients.
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib.
New
Impact
Schadendorf et al., Aş Şanamayn, Syria. In N Engl J Med, 16 Dec 2014
UNLABELLED: Background The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations.
A systematic review of genetic studies of thyroid disorders in Taiwan.
Review
New
Jap et al., Taipei, Taiwan. In J Chin Med Assoc, 11 Dec 2014
The prevalence of various somatic mutations in differentiated thyroid cancer was similar in Taiwan and Western countries, with the RAS kinase mutation and tyrosine receptor kinase (TRK) and rearranged during transfection (RET) proto-oncogenes being detected in lower frequencies and the B-type RAF kinase (BRAF) mutation accounting for the majority of cases.
Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma.
Review
New
Karagiannis et al., London, United Kingdom. In Mol Cancer Ther, 10 Dec 2014
Almost 50% of melanomas harbor targetable activating mutations of BRAF that promote RAS-RAF-MEK-ERK pathway activation and melanoma proliferation.
Targeted therapy: A new hope for thyroid carcinomas.
Review
New
Caponigro et al., Napoli, Italy. In Crit Rev Oncol Hematol, 01 Dec 2014
RET/PTC mutations are often discovered both in papillary and in medullary carcinomas, while B-RAF mutation is typical of papillary and anaplastic histologies.
Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series.
Review
New
Middleton et al., Oxford, United Kingdom. In Ther Adv Med Oncol, 30 Nov 2014
The selective BRAF inhibitors, vemurafenib and dabrafenib, yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma.
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy.
Review
New
van Amerongen et al., Amsterdam, Netherlands. In Cancer Res, 15 Nov 2014
UNLABELLED: Mutations in BRAF are present in the majority of patients with melanoma, rendering these tumors sensitive to targeted therapy with BRAF and MEK inhibitors.
[Adverse Effects of Modern Treatment of Malignant Melanoma and their Treatment/ Management.]
New
Kopecký et al., In Klin Onkol, Dec 2013
This could contribute to a prompt management of associated symptoms or an early referral of the patient to an appropriate clinical centre without undue delay.Key words: melanoma - immunotherapy - targeted therapy - side effects - BRAF inhibitor - anti-CTLA-4 -anti-PD-1 - MEK inhibitor The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
GeneRIF
Pritchard et al., Leicester, United Kingdom. In Genes Dev, 2012
endogenous expression of (L597V)Braf leads to approximately twofold elevated Braf kinase activity and weak activation of the Mek/Erk pathway
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.
GeneRIF
Eberhart et al., Baltimore, United States. In J Neuropathol Exp Neurol, 2012
The results of this study supported an important role for BRAF duplication and MAPK pathway activation in gliomas of the optic nerve proper.
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Review
GeneRIF
Xing et al., Baltimore, United States. In Medicine (baltimore), 2012
Thus, in this meta-analysis, the BRAF mutation in PTC was significantly associated with PTC recurrence, lymph node metastasis, extrathyroidal extension, and advanced stage AJCC III/IV.
KRAS and BRAF mutations in Serbian patients with colorectal cancer.
GeneRIF
Jankovic et al., Belgrade, Serbia. In J Buon, 2012
the spectrum and frequency distribution of the identified KRAS and BRAF mutations in Serbian patient with colorectal cancer are in good accordance with literature data.
A cardio-facio-cutaneous syndrome case with tight Achilles tendons.
GeneRIF
Ozkinay et al., İzmir, Turkey. In Genet Couns, 2011
Cardio-facio-cutaneous syndrome is caused by heterogeneous mutations in BRAF gene.
share on facebooktweetadd +1mail to friends